Search Results

United Therapeutics Corporation and Miromatrix Medical Inc. announced a definitive agreement for United Therapeutics to acquire Miromatrix.

United Therapeutics Corporation and Miromatrix Medical Inc. announced the results of the previously announced tender offer by Morpheus Subsidiary Inc., a wholly owned subsidiary of United Therapeutics, to acquire all outstanding shares of Miromatrix.

United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger.

Miromatrix Medical Inc. (Nasdaq: MIRO) (the “Company”), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today reported third quarter 2023 financial results.

Miromatrix Medical Inc. (NASDAQ: MIRO) today announced that it will be presenting at the 2023 International Society for Organ Donation and Procurement (“ISODP”) Organ Donation Congress in Las Vegas, NV on October 18-21 at Mandalay Bay Resort.

Miromatrix Medical Inc. today announced that it has commenced an underwritten public offering of shares of its common stock.

Miromatrix Medical Inc. announced its participation in the upcoming Alliance for Regenerative Medicine Tissue Engineering and Therapeutics Workshop held on September 6, 2023.

Miromatrix Medical Inc., a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced that CEO Jeff Ross will present at the 2023 Cell & Gene Meeting on the Mesa in Carlsbad, CA.

Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $1.60 per share, before underwriting discounts and commissions.

Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today reported second quarter 2023 financial results and provided a corporate update.